Loading clinical trials...
Loading clinical trials...
A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis
Conditions
Interventions
Relugolix Combination Tablet
Locations
120
United States
Mobile
Mobile, Alabama, United States
Chandler
Chandler, Arizona, United States
Mesa
Mesa, Arizona, United States
Peoria
Peoria, Arizona, United States
Phoenix
Phoenix, Arizona, United States
Tucson
Tucson, Arizona, United States
Start Date
August 14, 2023
Primary Completion Date
July 1, 2029
Completion Date
September 1, 2030
Last Updated
August 6, 2025
NCT07472842
NCT07471373
NCT05951452
NCT06611501
NCT07100782
NCT06974773
Lead Sponsor
Sumitomo Pharma Switzerland GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions